The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double blinded, placebo-controlled phase Ib clinical trial in adult
patients with immune thrombocytopenia. Cross-over treatment will be allowed during the study.